AURA

Aura Biosciences Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website aurabiosciences.com
Employees(FY) 70
ISIN US05153U1079

Performance

-2.84%

-8.07%

-15.38%

+16.31%

-7.45%

YTD

-3.07%

Profile

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of AURA 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 3 indicating strong bearish momentum, while the Oscillators Score of 46 suggests a neutral stance, and the Technical Score of 25 reinforces the bearish outlook. This combination signals caution for potential investors, as the prevailing trend leans towards...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AURA

Stock Rank

Recent News & Updates

2024-11-25 19:00
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference(Globenewswire)
2024-11-12 16:05
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights(GlobeNewswire)
2024-11-12 03:05
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-10-31 08:17
One Aura Biosciences Insider Raised Stake By 232% In Previous Year(Simply Wall St.)
2024-10-21 08:45
Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing(MT Newswires)
2024-10-17 16:05
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial(GlobeNewswire)
2024-10-17 04:05
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial(Globenewswire)
2024-10-04 07:38
Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58%(Simply Wall St.)
2024-09-13 09:30
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study(Zacks)
2024-09-12 09:10
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday(MT Newswires)
2024-09-12 07:24
Aura Biosciences' Eye Cancer Therapy Shows Promise in Mid-Stage Study -- Shares Rise Pre-Bell(MT Newswires)
2024-09-12 06:30
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma(GlobeNewswire)
2024-09-11 18:30
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma(Globenewswire)
2024-09-10 08:33
LifeSci Initiates Aura Biosciences at Outperform With $23 Price Target(MT Newswires)
2024-09-04 07:12
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate(Simply Wall St.)
2024-09-03 16:05
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024(GlobeNewswire)
2024-09-03 04:05
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024(Globenewswire)
2024-08-28 16:05
Aura Biosciences to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-08-28 04:05
Aura Biosciences to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-26 16:05
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting(GlobeNewswire)
2024-08-26 04:05
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting(Globenewswire)
2024-08-08 07:00
Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights(GlobeNewswire)
2024-08-07 19:00
Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-07-25 07:52
HC Wainwright Starts Aura Biosciences With Buy Rating, $21 Price Target(MT Newswires)
2024-06-06 09:55
Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?(Zacks)
2024-06-05 21:55
Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?(Zacks)
2024-05-30 16:05
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference(GlobeNewswire)
2024-05-30 04:05
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-23 08:00
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024(GlobeNewswire)
2024-05-22 20:00
Aura Biosciences to Host Virtual KOL Event Pioneering a New Standard of Care In Ocular Oncology on May 29, 2024(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.